ORBIMED ADVISORS LLC 4
4 · Sionna Therapeutics, Inc. · Filed May 29, 2026
Research Summary
AI-generated summary of this filing
Sionna (SION) Director OrbiMed Advisors Sells 101 Shares
What Happened OrbiMed Advisors LLC, reported as a director-related reporting person for Sionna Therapeutics (SION), sold 101 shares of Sionna common stock in an open-market disposition on May 27, 2026. The shares were sold at $44.49 per share for a total reported proceeds of $4,493. The filing indicates the sale was made pursuant to a 10b5-1 trading plan.
Key Details
- Transaction date: 2026-05-27 (reported on Form 4 filed 2026-05-29). Filing appears timely (filed within two business days).
- Transaction type/code: S = Sale (open market/private sale).
- Price and proceeds: 101 shares × $44.49 = $4,493.
- Shares owned after transaction: Not specified in the provided filing excerpt.
- Notable footnotes:
- F1: Sale executed under a 10b5-1 plan (prearranged trading plan).
- F2: Shares are held of record by OrbiMed Private Investments VIII, LP; OrbiMed Advisors and related entities may be deemed to have voting/investment power through their GP/management roles.
- F3: Form 4 is jointly filed by OrbiMed Advisors and the GP; each disclaims beneficial ownership except to the extent of pecuniary interest. Peter A. Thompson is OrbiMed’s designated board representative.
Context This is an institutional/manager sale executed under a 10b5-1 plan, which typically indicates preplanned, routine dispositions rather than discretionary, real-time decisions by an insider. The small dollar amount ($4.5k) is not a material stake change and, standing alone, is not a strong signal about company prospects.
Insider Transaction Report
- Sale
Common Stock
[F1][F2][F3]2026-05-27$44.49/sh−101$4,493→ 2,671,721 total(indirect: See footnotes)
Footnotes (3)
- [F1]These securities were sold pursuant to a 10b5-1 plan.
- [F2]These securities are held of record by OrbiMed Private Investments VIII, LP ("OPI VIII"). OrbiMed Capital GP VIII LLC ("GP VIII") is the general partner of OPI VIII and OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting and investment power with respect to the shares held by OPI VIII and as a result may be deemed to have beneficial ownership of such shares. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII.
- [F3]This report on Form 4 is jointly filed by OrbiMed Advisors and GP VIII. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Peter A. Thompson, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.